Please try another search
The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It has a policy of investing at least 25% of its assets in investments in the medical research and health care industry.
Name | Title | Since | Until |
---|---|---|---|
Jason A. Kritzer | Vice President | 2016 | Now |
Biography | Mr. Kritzer is a Vice President of Eaton Vance. Prior to joining Eaton Vance in 2012, Mr. Kritzer was a director and equity analyst at BlackRock , Inc. covering the healthcare sector since 2006. | ||
Samantha Pandolfi | Vice President | 2016 | Now |
Biography | Ms. Pandolfi is a Vice President of EVAIL. Prior to joining EVAIL, Ms. Pandolfi held similar positions at EVMI. Prior to joining EVMI as a Vice President in November 2015, Ms. Pandolfi was a Portfolio Manager and Research Analyst with Goldman Sachs Asset Management over her fifteen year tenure (2000-2015). | ||
Sven H. Borho | Founding General Partner | 2005 | 2016 |
Biography | Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed’s public equity funds and he heads the firm’s trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden. | ||
Richard D. Klemm | Biotechnology Analyst | 2005 | 2016 |
Biography | Klemm joined OrbiMed in 2000 as a biotechnology analyst. Klemm has earned the right to use the Chartered Financial Analyst designation. | ||
Geoffrey C. Hsu | Biotechnology Analyst | 2005 | 2016 |
Biography | Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation. | ||
Trevor M. Polischuk | Analyst | 2005 | 2016 |
Biography | Polischuk joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry. | ||
Samuel David Isaly | Portfolio Manager | 1985 | 2016 |
Biography | Samuel D. Isaly founded Exome in 2018 and is the Managing Member. Mr. Isaly is one of the world’s most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Isaly was a portfolio manager with OrbiMed Advisors. Previously, he was a president and partner with Mehta and Isaly Asset Management. From 1986 to 1989, he was a senior vice president with S.G. Warburg & Company. He also spent more than three years as a partner with Gramercy Associates, one and a half years as a vice president with Merrill Lynch & Company, and two years as a vice president with Chase Manhattan Bank. | ||
Bernard Graham | - | 1985 | 1989 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review